In 2018, the splice variant (rs72613567:TA) in HSD17B13 gene, encoding the hydroxysteroid 17-β dehydrogenase 13, was discovered to be associated with protection against histological steatohepatitis, fibrosis and cirrhosis in both NAFLD and ALD patients [149]. Here, HSD17B13 is linked to metabolic dysfunction-associated steatotic liver disease.